The effects of bivalent human papillomavirus (HPV) vaccination on high-risk anogenital HPV infection among sexually active female adolescents with and without perinatally acquired HIV
Pradthana Ounchanum
A * , Jullapong Achalapong A , Sirinya Teeraananchai B , Sivaporn Gatechompol C D , Wanatpreeya Phongsamart E , Kulkanya Chokephaibulkit E , Dan Ngoc Hanh Tran F , Hanh Le Dung Dang G , Nipat Teeratakulpisarn H , Amphan Chalermchockcharoenkit E , Thida Singtoroj I , Annette H. Sohn I * and Nittaya Phanuphak H
A
B
C
D
E
F
G
H
I
Handling Editor: Huachun Zou
Abstract
Females with perinatal HIV (PHIV) infection are at elevated risk for anogenital high-risk human papillomavirus (HR-HPV) infection. Limited data are available around the effect of the HPV vaccination after initiation of sexual activity among PHIV youth. This study aims to assess the impact of a bivalent HPV vaccination on the persistence of anogenital HR-HPV among sexually active female PHIV youth and matched HIV-negative controls aged 12–24 years in Thailand and Vietnam.
During a 3-year study, prevalent, incident, and persistent HR-HPV infection were assessed at annual visits. A subset of participants received a bivalent HPV vaccine. Samples were taken for HPV testing from the vagina, cervix, and anus. HR-HPV persistence was defined as the detection of the same genotype(s) at any anogenital compartment over ≥ two consecutive visits.
Of the 93 PHIV and 99 HIV-negative female youth enrolled in this study, 25 (27%) PHIV and 22 (22%) HIV-negative youth received a HPV vaccine. Persistent infection with any HR-HPV type was significantly lower among PHIV youth who received the vaccine compared to those who did not (33% vs 61%, P = 0.02); a difference was not observed among HIV-negative youth (35% vs 50%, P = 0.82). PHIV infection (adjusted prevalence ratio [aPR] 2.31, 95% CI 1.45–3.67) and not receiving a HPV vaccine (aPR, 1.19, 95%CI 1.06–1.33) were associated with persistent anogenital HR-HPV infection.
Bivalent HPV vaccination after initiation of sexual activity was associated with reduced persistence of anogenital HR-HPV infection in Southeast Asian PHIV female youth, which may be related to vaccine cross-protection. Primary and catch-up HPV vaccinations should be prioritised for children and youth with HIV.
Keywords: adolescent, anogenital, bivalent, HIV, human papillomavirus, perinatal, sexually active, vaccination.
References
1 de Villiers E-M, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27.
| Crossref | Google Scholar | PubMed |
2 Silva Dalla Libera L, Almeida de Carvalho KP, Enocencio Porto Ramos J, et al. Human papillomavirus and anal cancer: prevalence, genotype distribution, and prognosis aspects from Midwestern Region of Brazil. J Oncol 2019; 2019: 6018269.
| Crossref | Google Scholar |
3 Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses 2017; 9: 229.
| Crossref | Google Scholar |
4 Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123-137.
| Crossref | Google Scholar | PubMed |
5 Poljak M, Šterbenc A, Lunar MM. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV). Expert Rev Anti-infect Ther 2017; 15: 987-999.
| Crossref | Google Scholar | PubMed |
6 Sohn AH, Kerr SJ, Hansudewechakul R, et al. Risk factors for human papillomavirus infection and abnormal cervical cytology among perinatally human immunodeficiency virus-infected and uninfected Asian youth. Clin Infect Dis 2018; 67: 606-613.
| Crossref | Google Scholar |
7 Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
| Crossref | Google Scholar | PubMed |
8 Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
| Crossref | Google Scholar | PubMed |
9 Ruiz-Sternberg ÁM, Moreira ED, Jr, Restrepo JA, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res 2018; 5: 63-74.
| Crossref | Google Scholar | PubMed |
10 World Health Organization. Immunization, vaccines and biologicals. HPV. 2017. Available at http://www.who.int/immunization/diseases/hpv/en/
11 Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018; 5 CD009069.
| Crossref | Google Scholar |
12 McClymont E, Lee M, Raboud J, et al. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus. Clin Infect Dis 2019; 68(5): 788-794.
| Crossref | Google Scholar | PubMed |
13 Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012; 344: e1401.
| Crossref | Google Scholar |
14 Klinsupa W. HPV vaccine introduction in Thailand. Expanded Program on Immunization, Ministry of Health Thailand. 2014. Available at https://www.eiseverywhere.com/file_uploads/7a51c93d87fa9a3600be1cc805d5941a_WorrawanKlinsupa.pdf
15 Ladner J, Besson M-H, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries. BMC Public Health 2014; 14: 670.
| Crossref | Google Scholar |
